NASDAQ:ORTX

Orchard Therapeutics Stock Forecast, Price & News

$5.03

-0.09 (-1.76 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.01

▼

$5.20

50-Day Range

$5.00

▼

$7.11

52-Week Range

$3.76

▼

$9.08

Volume1.23 million shs

Average Volume1.49 million shs

Market Capitalization$622.56 million

P/E RatioN/A

Dividend YieldN/A

Beta1.16

30 days | 90 days | 365 days | Advanced Chart

Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Orchard Therapeutics

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orchard Names Patrick McClymont as Chief Financial Officer to Accelerate Company Growth
June 15, 2021 | markets.businessinsider.com

U-pick at Lehman’s Orchard open for season
June 14, 2021 | msn.com

Orchard Park man arrested after 3-car crash at Broadway, Elm Street
June 14, 2021 | msn.com

ION Orchard to close from Saturday for 4 days due to COVID cases
June 11, 2021 | msn.com

New Hampshire man accused of stealing car in Old Orchard Beach, attempted carjacking in Saco
June 10, 2021 | msn.com

New Hampshire accused of stealing car in Old Orchard Beach, attempted car jacking in Saco
June 10, 2021 | msn.com

Driver crashes into Dairy Queen building in Orchard Mesa
June 9, 2021 | msn.com

Bills stay in Orchard Park for training camp
June 7, 2021 | msn.com

Crash involving wrong-way driver partially blocks eastbound SR 16 near Port Orchard
June 6, 2021 | msn.com

Blake's Orchard & Cider Mill marks its anniversary with free doughnuts and special pricing
June 3, 2021 | msn.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORTX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.orchard-tx.com
Phone011-44-0-203-3846700
Employees224
Year FoundedN/A

Sales & Book Value

Annual Sales$2.60 million
Price / Sales239.45
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.82 per share
Price / Book2.76

Profitability

EPS (Most Recent Fiscal Year)($1.53)
Net Income$-151,980,000.00
Net MarginsN/A
Return on Equity-60.17%
Return on Assets-42.59%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares123,769,000
Market Cap$622.56 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.45 out of 5 stars

Medical Sector

651st out of 2,100 stocks

Biological Products, Except Diagnostic Industry

85th out of 198 stocks

3.5 Analyst's Opinion

Consensus Rating
Orchard Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Orchard Therapeutics has a forecasted upside of 198.2% from its current price of $5.03.
Amount of Analyst Coverage
Orchard Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Orchard Therapeutics has received 143 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Orchard Therapeutics has received 171 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Orchard Therapeutics has received 54.46% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote “Outperform” if you believe ORTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Orchard Therapeutics does not currently pay a dividend.
Dividend Growth
Orchard Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Orchard Therapeutics is held by insiders.
Percentage Held by Institutions
64.73% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Orchard Therapeutics are expected to grow in the coming year, from ($1.34) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Orchard Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Orchard Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Orchard Therapeutics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

Is Orchard Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Orchard Therapeutics stock.
View analyst ratings for Orchard Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Orchard Therapeutics?

Wall Street analysts have given Orchard Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orchard Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Orchard Therapeutics.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings results on Thursday, May, 13th. The company reported ($0.31) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.02.
View Orchard Therapeutics' earnings history.

How has Orchard Therapeutics' stock price been impacted by Coronavirus?

Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ORTX stock has decreased by 44.6% and is now trading at $5.03.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ORTX?

4 brokers have issued 12 month price objectives for Orchard Therapeutics' shares. Their forecasts range from $12.00 to $17.00. On average, they anticipate Orchard Therapeutics' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 198.2% from the stock's current price.
View analysts' price targets for Orchard Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:

Dr. Bobby Gaspar Ph.D., M.D., CEO, Member of Scientific Advisory Board & Exec. Director (Age 56, Pay $519.47k)
Mr. Frank E. Thomas, Pres & COO (Age 51, Pay $691.24k)
Ms. Renee T. Leck, Director of Investor Relations
Mr. John Ilett, Chief of Staff, Chief Legal Officer & Company Sec.
Molly Cameron, Mang. of Corp. Communications
Mr. John Cerio, Chief Human Resource Officer
Dr. Anne Dupraz-Poiseau, Chief Devel. Officer
Mr. Adrien Lemoine, Chief Bus. Officer
Mr. Robin Kenselaar, Sr. VP & GM of EMEA Commercial Operations
Mr. Braden Parker, Chief Commercial Officer

Who are some of Orchard Therapeutics' key competitors?

Some companies that are related to Orchard Therapeutics include bluebird bio (BLUE), Kymera Therapeutics (KYMR), Instil Bio (TIL), C4 Therapeutics (CCCC), Sangamo Therapeutics (SGMO), Immunocore (IMCR), BioAtla (BCAB), Replimune Group (REPL), Translate Bio (TBIO), REGENXBIO (RGNX), Alector (ALEC), Krystal Biotech (KRYS), Cortexyme (CRTX), AlloVir (ALVR) and Valneva (VALN).
View all of ORTX's competitors.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (8.60%), JPMorgan Chase & Co. (3.84%), Lord Abbett & CO. LLC (1.43%), Sphera Funds Management LTD. (1.13%), New York State Common Retirement Fund (1.05%) and Baker BROS. Advisors LP (0.61%).
View institutional ownership trends for Orchard Therapeutics.

Which institutional investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Morgan Stanley, Goldman Sachs Group Inc., Platinum Investment Management Ltd., Forefront Analytics LLC, Mutual of America Capital Management LLC, Squarepoint Ops LLC, and Ameriprise Financial Inc..
View insider buying and selling activity for Orchard Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Orchard Therapeutics stock?

ORTX stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Lord Abbett & CO. LLC, Sphera Funds Management LTD., JPMorgan Chase & Co., New York State Common Retirement Fund, Rafferty Asset Management LLC, Baker BROS. Advisors LP, and GSA Capital Partners LLP.
View insider buying and selling activity for Orchard Therapeutics or or view top insider-buying stocks.

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $5.03.

How much money does Orchard Therapeutics make?

Orchard Therapeutics has a market capitalization of $622.56 million and generates $2.60 million in revenue each year. The company earns $-151,980,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 224 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

Where are Orchard Therapeutics' headquarters?

Orchard Therapeutics is headquartered at 108 CANNON STREET, LONDON X0, EC4N 6EU.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700.

This page was last updated on 6/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here